



Universiteit
Leiden

The Netherlands

Disrupting the transcriptional machinery to combat triple-negative breast cancer

Noord, V.E. van der

Citation

Noord, V. E. van der. (2024, April 25). *Disrupting the transcriptional machinery to combat triple-negative breast cancer*. Retrieved from <https://hdl.handle.net/1887/3748390>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3748390>

Note: To cite this publication please use the final published version (if applicable).

Chapter 2

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer

Vera E. van der Noord^{1, 3}, Ronan P. McLaughlin^{1, 3}, Marcel Smid², John A. Foekens², John W.M. Martens², Yinghui Zhang¹, Bob van de Water¹

Scientific Reports (2019), 9(1), 13308.

¹)Division of Drug Discovery and Safety, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands ²)Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands ³) These authors contributed equally to the work.

Highlights:

- TNBC cell lines exhibit three distinct response clusters to MEK and Akt inhibitors: resistance to MEK inhibition, resistance to Akt inhibition, or resistance to both MEK and Akt inhibitors
- Discrimination between Akt inhibitor-resistant and MEK inhibitor-resistant cell lines is informed by the activity and mutations within PI3K-MAPK pathway members
- Akt/MEK inhibitor double-resistant cell lines are characterized by an elevated and clinically relevant expression network of cell cycle genes, which provides new targets to bypass resistance

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor clinical prognosis and limited targeted treatment strategies. Kinase inhibitor screening of a panel of 20 TNBC cell lines uncovered three critical TNBC subgroups: 1) sensitive to only MEK inhibitors; 2) sensitive to only Akt inhibitors; 3) resistant to both MEK/Akt inhibitors. Using genomic, transcriptomic and proteomic datasets of these TNBC cell lines we unravelled molecular features associated with the MEK and Akt inhibitor drug resistance. MEK inhibitor-resistant TNBC cell lines were discriminated from Akt inhibitor-resistant lines by the presence of PIK3CA/PIK3R1/PTEN mutations, high p-Akt and low p-MEK levels, yet these features could not distinguish double-resistant cells. Gene set enrichment analyses of transcriptomic and proteomic data of the MEK and Akt inhibitor response groups revealed a set of cell cycle-related genes associated with the double-resistant phenotype; these genes were overexpressed in a subset of breast cancer patients. CDK inhibitors targeting the cell cycle programme could overcome the Akt and MEK inhibitor double-resistance. In conclusion, we uncovered molecular features and alternative treatment strategies for TNBC that are double-resistant to Akt and MEK inhibitors.

Introduction

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is defined by the absence of the estrogen receptor (ER), progesterone receptor (PR) and the lack of overexpression or gene amplification of the human epidermal growth factor receptor 2 (HER2)¹. TNBC comprises a clinically and molecularly heterogeneous group of breast cancers and accounts for approximately 15% of all breast cancer cases. Although TNBC patients more often show a complete response after neo-adjuvant chemotherapy and surgery compared to other breast cancer subtypes, still >60% of the patients do not achieve a complete remission². Due to the aggressive nature of this disease and the lack of targeted therapy, these unresponsive TNBC patients have worse event-free and overall survival rates compared to other subtypes³. Developing effective targeted therapies for TNBC patients is thus crucial for reducing the mortality rate of this aggressive subtype.

TNBC tumours commonly have either activating mutations or amplifications of PIK3CA, BRAF, KRAS and/or EGFR and/or PTEN loss, causing abnormal activity of the Raf/MAPK/ERK or PI3K/Akt/mTOR pathway^{4,5}. Inhibition of these pathways using MEK and/or Akt inhibitors is thus an attractive strategy for treating TNBC⁶. However, resistance to these inhibitors is often observed in pre-clinical studies⁷⁻¹⁰. Efforts to overcome this resistance include reversing possible drug-induced loss of negative feedback, by combining MEK and Akt or PI3K inhibitors, or one of these with epidermal growth factor receptor (EGFR) inhibitors⁷⁻¹³. These strategies have now reached clinical trials, but their benefits remain elusive^{13,14}. Another challenge is the prediction of response to provide patients with optimal, personalised, treatment strategies. Var-

ious studies demonstrate that mutations in RAS and BRAF are associated with MEK inhibitor sensitivity and mutations in RAS, PIK3CA or PTEN are associated with Akt inhibitor sensitivity⁷⁻⁹. Yet, these features do not completely correlate with sensitivity in (pre-)clinical studies in TNBC and other malignancies¹³. Novel insights in predicting the response and providing alternatives to drug-resistant tumours are thus essential in facilitating the clinical development of such inhibitors in TNBC.

In this study, comparing the efficacy of various kinase inhibitors with multiple targets, we found that TNBC cell lines respond differentially to MEK and Akt inhibitors. By assessing TNBC cell line groups that had different response patterns to these inhibitors, we have shown that Akt or MEK inhibitor sensitivity can be distinguished by the presence of mutations in the PI3K pathway and activity of the PI3K and MAPK pathway. By performing a large-scale gene set enrichment analysis, we found that Akt and MEK inhibitor double resistance is associated with elevated expression of cell cycle genes. On the other hand, MEK and Akt inhibitor double-resistant cell lines were more, but not exclusively, sensitive to inhibitors of this network, such as dinaciclib and flavopiridol, which may constitute alternative treatment options for this TNBC subgroup. Our results thus shed light on a gene network associated with resistance to MEK and Akt inhibitors and provide potential markers of response as well as alternative treatments.

Methods

Cell culture

Twenty human TNBC cell lines were used, including BT20, BT549, HCC1143, HCC1806, HCC1937, HCC38, HCC70, Hs578T, MDA-MB-231, MDA-MB-435s, MDA-MB-436, MDA-MB-453, MDA-MB-468, SKBR7, SUM1315M02, SUM149PT, SUM159PT, SUM185PE, SUM229PE and SUM52PE. All cells were cultured in RPMI-1640 medium containing L-glutamine and 25 mM HEPES (Gibco Fisher Scientific, Landsmeer, The Netherlands) supplemented with 10% fetal bovine serum (FBS), 25 U/mL penicillin and 25 µg/mL streptomycin (Fisher Scientific) in a humidified incubator with 5% CO₂ at 37°C.

Cell line characteristics and annotation

To reflect the heterogeneity in TNBC, the cell lines used in this study comprised multiple TNBC classes, including the basal-like type 1 (BL1; HCC1937, HCC1143, MDA-MB-468 and HCC38) and 2 (BL2; SUM149PT, HCC70, HCC1806), mesenchymal (M; BT549) and mesenchymal-like (MSL; Hs578T, SUM159PT, MDA-MB-436, MDA-MB-231) and luminal androgen receptor (LAR; MDA-MB-453, SUM185PE) subtypes, as defined by Lehmann et al¹⁵. Additional cell lines that were not previously classified in subtypes were also used (BT20, MDA-MB-435s, SKBR7, SUM1315M02, SUM229PE and SUM52PE). Cell lines from the immunomodulatory subtype were not included, as these cell lines (DU4775, HCC1187) grow in (mixed) suspension. Other TNBC cell lines, including CAL-51, CAL-120, CAL-148, CAL-851, HCC1395,

Chapter 2

HCC1599, HCC2157, HCC2185, HCC3153, HDQ-P1, MDA-MB-157, MFM-223 and SW527 were not used in this study due to technical considerations (e.g. limited proliferation, growing in (mixed) suspension cultures and availability). Cell line mutations were derived from the COSMIC database cell line project³³.

Reagents and antibodies

For screening and primary validations with MEK and Akt inhibitors, a library of 378 kinase inhibitors was used (L1200 library; Selleckchem, Huissen, The Netherlands, Supplementary Dataset 1). A concentration of 1 μ M kinase inhibitor was used for the primary screening in the 20 TNBC cell lines. For further validation and other experiments, selumetinib (S1008), AZD8330 (S2134), PD184352 (S1020), MK-2206 (S1078), AZD5363 (S8019) and ipatasertib (GDC-0068; S2808) were purchased from Selleckchem.

The mouse antibody against MEK1/2 (4694S) and rabbit antibodies against phospho-MEK1/2 (Ser217/221, 9120), phospho-Akt (Ser473, 9271), phospho-p44/42 MAPK (ERK1/2, Thr202/Tyr204, 9101), phospho-mTOR (Ser2448, 5536S), Akt (9272), p44/42 MAPK (Erk1/2, 4695) were purchased from Cell Signaling (Leiden, The Netherlands). The mouse antibody against α -tubulin (T-9026) was from Sigma-Aldrich. Secondary goat antibodies horseradish peroxidase (HRP)-linked anti-rabbit (111-035-003) and anti-mouse (115-035-003) and Alexa-647-linked anti-mouse (115-605-146) were purchased from Jackson Immunoresearch (Bio-Connect, Huissen, The Netherlands).

Cell proliferation assays

Cell proliferation was determined using a sulforhodamine B (SRB) colorimetric assay as described previously³¹. TNBC cell lines were plated at optimal cell densities ranging from 4,000 to 18,000 cells in 96-well plates and allowed to attach overnight before treatment. Cells were treated with kinase inhibitors for 4 days and thereafter fixed by adding 30 μ L 50% trichloroacetic acid (TCA; Sigma-Aldrich). Cellular proteins were stained with 0.4% SRB (Sigma-Aldrich) and unbound SRB was removed with 1% acetic acid (VWR, Amsterdam, The Netherlands). Protein-bound SRB was solubilised in 10 mM aqueous unbuffered Tris (Fischer Scientific) and SRB absorbance was measured at 540 nm on an Infinite M1000 microplate reader (Tecan, Giessen, The Netherlands). Dose response curves and IC₅₀ values were generated in GraphPad Prism (version 7.01).

Protein extraction and western blotting

Protein extraction and western blotting were conducted as described before³². Cellular proteins (20 μ g/lane) were loaded on 7.5% polyacrylamide gels for SDS-PAGE. After electrophoresis, proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Milipore, Amsterdam, The Netherlands) overnight and blocked in 5% bovine serum albumin (BSA; Sigma Aldrich) in Tris-buffered saline with 0.05% Tween (TBS-T0.05). Primary and secondary antibodies were dissolved in 1% BSA in TBS-

T0.05. Using an Amersham Imager 600 (GE Healthcare Life Sciences, Eindhoven, The Netherlands) Alexa Fluor 647-conjugated antibodies were visualised by Cy5 fluorescence and HRP-conjugated antibodies by chemiluminescence after staining with ECL (Prime) Western Blotting Detection Reagent (GE Healthcare Life Sciences). Signal intensities were quantified using ImageJ.

Gene set enrichment analysis (GSEA) of TNBC cell lines

TNBC cell line mRNA microarray data were previously established³⁴. In short, raw data (.CEL files) were processed using the robust multi-array average (RMA) method and data are available in the Gene Expression Omnibus data repository (Accession number: GSE41313). Protein abundance in the TNBC cell lines was previously analysed using high-end proteomics (Manuscript in preparation, data available upon request). Data were log-transformed ($\log_2$) and gene set enrichment was evaluated using GSEA software^{35,36}. Enrichment of canonical pathways was tested using the curated c2cp gene sets from KEGG and Reactome (1,000 permutations per gene set). To visualise the significantly enriched gene sets ($P < 0.005$, FDR Q-value < 0.1) Cytoscape was used to organise these in enrichment maps (similarity cut-off > 0.7)³⁷. For all the enriched gene sets involved in cell cycle, the genes that were core enriched (signal-to-noise score > 0.1) were collected and used for plotting heatmaps of their expression in TNBC cell lines (mRNA and protein expression) and breast cancer patients (mRNA). Overlapping networks of these genes from mRNA and protein expression were made by retrieving their network in STRING (v10.0) and providing colour annotation in Cytoscape. Pathway mapping of the core enriched genes was performed in Ingenuity Pathway Analysis (IPA) software (QIAGEN Bioinformatics).

Gene expression in breast cancer patients

RNA sequencing and clinical data of breast cancer patients were retrieved from the TCGA database in R using the TCGAbiolinks package from Bioconductor³⁸. Normalised RNA sequencing data from Illumina HiSeq platforms from primary solid tumour samples of the TCGA-BRCA project were downloaded. Cell cycle genes that were established as described in the previous section were used for generating heatmaps for both all breast cancer ($n=1093$) and TNBC patients ($n=120$) specifically. TNBC patients were selected on the absence of HER2, ER and PR, as annotated in the TCGA data.

Statistical analysis

All heatmaps and hierarchical clusters were generated using the CRAN pheatmap package in R studio (version 3.3.1)³⁹. Statistical analysis of grouped western blot outcomes with replicated measurements was performed using a two-way ANOVA in GraphPad Prism (Version 7). Significance was set at $P < 0.05$. IC50 values were also calculated in GraphPad Prism.

Results

TNBC cell lines cluster into three groups based on responses to MEK and Akt inhibitors

To explore heterogeneity in targeted therapy responses, we evaluated the proliferative responses to 378 kinase inhibitors in 20 TNBC cell lines. To capture the heterogeneity in TNBC disease, these cell lines comprised multiple TNBC classes, including the basal-like, mesenchymal-like and luminal androgen receptor subtypes¹⁵. The TNBC cell lines largely demonstrated resistance to these inhibitors, but some inhibitors differentially affected the proliferation of the cell lines (Figure 1A, Supplementary Dataset 1). In particular the responses to inhibitors of MEK and Akt were heterogeneous (Figure 1A, black box, Supplementary Figure S1), classifying the TNBC cell lines into three subgroups (Figure 1B): cell lines were either resistant to Akt inhibitors, but sensitive to MEK inhibitors (Group 1, Akt-i-resistant); resistant to MEK inhibitors, but sensitive to Akt inhibitors (Group 2, MEK-i-resistant); or resistant to both Akt and MEK inhibitors (Group 3, Akt-i/MEK-i double-resistant). At the used concentration of 1 μ M, we did not find a clear clustering of the related Raf and PI3K inhibitors (Supplementary Dataset 1 and Supplementary Figure S2). For example, while Raf inhibitors TAK-632 and RAF265 resulted in similar effects on the TNBC cell lines as the MEK inhibitors, Raf inhibitor vemurafenib induced opposite responses.

To further validate the Akt-i/MEK-i response classifications, we treated the TNBC cell lines with a dose range of the various MEK and Akt inhibitors (Figure 1C and Supplementary Figure S3). MEK inhibition effectively reduced the growth of Akt-i-resistant Group 1 cells at low concentrations (IC₅₀s~10 nM, Supplementary Table S1), but not of MEK-i-resistant Group 2 or Akt-i/MEK-i-resistant Group 3 cells. Whereas Akt inhibitors affected the cell proliferation of MEK-i-resistant Group 2 cell lines (IC₅₀s~0.1-1 μ M), Akt-i-resistant Group 1 and Akt-i/MEK-i double-resistant Group 3 cell lines did not respond to these inhibitors (IC₅₀s>3.16 μ M).

Activity and mutations of PI3K-MAPK pathway members distinguish between Akt-i-resistant and MEK-i-resistant cell lines

To understand the differential sensitivity to Akt and MEK inhibitors, we evaluated the basal phosphorylation levels of signalling components involved in the PI3K and MAPK pathways. Akt-i-resistant Group 1 cell lines expressed significantly higher levels of p-MEK compared with MEK-i-resistant Group 2 cell lines ($P=0.0003$, Figure 2A and B). In contrast, Group 2 cell lines expressed higher levels of p-Akt compared with Group 1 cell lines ($P=0.0072$). Levels of p-Akt and p-MEK thus distinguish between Group 1 and 2 cell lines, suggesting that these groups exhibit a greater dependence on MAPK- or PI3K-mediated signalling, respectively, which may therefore account for the differential sensitivity of these groups to MEK and Akt inhibitors. Akt-i/MEK-i-resistant cell lines showed an average trend of increased p-Akt compared with Group 1 ($P=0.0315$) and increased p-MEK compared with Group 2 ($P<0.0001$) cell lines, respectively. However, Akt-i/MEK-i-resistant Group 3 cell line SUM159PT had low




Figure 1. Proliferation of TNBC cell lines in response to MEK and Akt inhibitors. (A) A heatmap of proliferative responses of TNBC cell lines to kinase inhibitors (1 μ M). Low Z-scores (red) indicate reduced cell growth, whereas high Z-scores indicate resistance (blue). The black box highlights mainly MEK and Akt inhibitors. (B) Clustering of responses to Akt and MEK inhibitors from this black box of TNBC cell lines among Group 1 (Akt-i-resistant), Group 2 (MEK-i-resistant) and Group 3 (Akt-i/MEK-i-resistant) cell lines. Abbreviations of TNBC subtypes: luminal androgen receptor (LAR), basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal stem-like (MSL), mesenchymal (M). (C) Dose responses of TNBC cell line groups to the Akt and MEK inhibitors (0.01–3.16 μ M). Data are expressed as means $\pm$ SD from two independent experiments.




Figure 2. Basal levels of p-Akt and p-MEK in TNBC and drug resistance. (A) Western blot analysis and (B) quantification of p-Akt and p-MEK levels in the Akt-i-resistant, MEK-i-resistant and double-resistant cell lines. P-Akt and p-MEK levels were normalised to tubulin. Data are expressed as means $\pm$ SD of two independent experiments (two-way ANOVA, * P <0.05, ** P <0.01, *** P <0.001, **** P <0.0001).

levels of p-MEK, indicating that this average trend is not completely discriminative. Therefore, p-Akt and p-MEK levels alone cannot discriminate between Akt-i/MEK-i double-resistant and MEK- or Akt-i-sensitive cell lines.

Next, we evaluated the mutations present in the relevant genes in the three groups to further understand the differential phenotypes. All MEK-i-resistant Group 2 cell lines with high levels of p-Akt had mutations in PTEN, PIK3CA and/or PIK3R1 (6/6) (Supplementary Table S2). These mutations were completely absent in the Akt-i-resistant Group 1 cell lines (0/7). Akt-i/MEK-i-resistant Group 3 cell lines had a mixed mutational profile (5/7). In addition, Group 1 cell lines exhibited a higher frequency of BRAF mutations upstream of MEK (2/7), whereas these were absent in both Group 2 (0/6) and Group 3 (0/7) cell lines. Mutations in KRAS or HRAS did not differentiate between any of the groups (Group 1: 2/7, Group 2: 1/6 and Group 3: 2/7). Altogether, these features could distinguish between Akt-i and MEK-i resistance, but do not explain Akt-i/MEK-i double resistance.

Crosstalk between Akt and MEK is not essential for Akt-i/MEK-i resistance

To further explore this Akt-i/MEK-i double-resistant phenotype, we investigated the role of crosstalk between Akt and MEK pathways. If crosstalk would drive the resistant phenotype, the double-resistant, but not single-resistant, cell lines would show

increased levels of active MEK/ERK upon Akt inhibition, and vice versa. Moreover, an improved, synergistic, response would be expected upon combination treatment. Treatment with ATP non-competitive MEK inhibitors selumetinib and PD184352 resulted in accumulation of p-MEK accompanied by inhibition of ERK phosphorylation in all cell lines (Figure 3A). The extent of inhibition of ERK phosphorylation was similar across the cell line panel, indicating that MEK-i resistance is not related to a




Figure 3. Cooperation of Akt and MEK signalling in TNBC proliferation. (A) Western blot analysis after inhibition by MEK inhibitors (selumetinib and PD184352) and Akt inhibitors (ipatasertib and MK-2206). Cells were treated with inhibitors (1 μ M) for 24 hours. Data are representative of two independent experiments. (B) Combined inhibition by increasing concentrations of selumetinib or ipatasertib (0.00316–10 μ M), together with a fixed concentration of ipatasertib or selumetinib (1 μ M), respectively. Data are expressed as means $\pm$ SD from three independent experiments.

lack of target inhibition. The allosteric Akt1/2/3 inhibitor MK-2206 fully prevented Akt phosphorylation in all cell lines, whilst ATP-competitive Akt1/2/3 inhibitor ipatasertib caused accumulation of p-Akt, as binding of this inhibitor to the active site protects Ser473 phosphorylation sites from phosphatases¹⁶. This implies that resistance to these agents is also not due to a lack of target inhibition. The Akt inhibitors reduced p-mTOR levels in some, but not all cell lines, an event which was independent of Akt-i or MEK-i sensitivity status, suggesting mTOR activity is not critical in conferring resistance to such inhibitors. Akt inhibition slightly increased p-MEK levels in Akt-i-resistant Group 1 cell lines, but not in Akt-i/MEK-i-resistant Group 3 cell lines.

Next, we evaluated whether combining MEK inhibitors with Akt inhibitors enhances the growth-inhibitory effects of either drug. Cell lines were treated with a combination of selumetinib (MEK-i) and ipatasertib (Akt-i). The combined treatment of a dose range of selumetinib, together with a fixed concentration of ipatasertib (1 μ M), and vice versa, did not overtly enhance the anti-proliferative effects of either agent in most cell lines (Figure 3B). The combination treatments moderately sensitised SUM159PT to either selumetinib or ipatasertib. For all of the Akt-i/MEK-i-resistant Group 3 cell lines, combination treatments were incapable of reducing cell proliferation to the same extent as in the Group 1 or Group 2 cell lines. Altogether, these results suggest that crosstalk or additive ERK and Akt proliferation signalling programs are not essential for the resistance observed in Akt-i/MEK-i-resistant Group 3 cell lines.

Akt-i/MEK-i-resistant cell lines can be distinguished by an elevated cell cycle gene expression network

As a next step we explored the possible signalling pathways that contribute to the double-resistant phenotype of the TNBC cell lines. Therefore, we systematically compared the previously established transcriptomes and proteomes of the three different TNBC cell panel groups. Gene set enrichment analysis (GSEA) revealed enriched gene sets in Akt-i/MEK-i-resistant Group 3 cell lines compared with both Akt-i-resistant Group 1 and MEK-i-resistant Group 2 cell lines (Figure 4A, Supplementary Figure S4 and S5 and Supplementary Dataset 2, respectively). The 37 and 62 significantly enriched gene sets ($p < 0.005$, FDR q -value < 0.1), based on mRNA and protein expression respectively, predominantly consisted of cell cycle-related gene sets. GSEA of protein expression data also revealed other enriched gene sets involved in translation, RNA and protein metabolism and the immune system. These gene sets overlapped (in)directly with the cell cycle related gene sets.

Within these significantly enriched cell cycle-related gene sets, we selected and explored the genes that contributed to the enrichment result (signal-to-noise ratio > 0.1) for both the transcriptomics (142 genes) and proteomics (102 genes) datasets (Figure 4B and 4C, Supplementary Table S3). These genes contribute to a variety of cell cycle processes, such as G1/S transition, G2/M transition, cell cycle regulation, ubiquitination and nuclear division, suggesting that the observed cell cycle enrichment is not due to a prolonged state of one specific cell cycle phase. The genes included, amongst others, cyclin-dependent kinases (CDK) 2, 4, 5, 6 and 9, cell-division cycle




Figure 4. Gene set enrichment analysis (GSEA) in the Akt-i/MEK-i-resistant cell lines. (A) mRNA (left) and protein (right) expression were compared between MEK and Akt inhibitor-resistant Group 3 versus MEK or Akt inhibitor-resistant Group 1 and 2 cell lines using GSEA. The enrichment maps visualise enriched gene sets ($P < 0.005$, FDR Q-value < 0.1 , overlap > 0.7), among which cell cycle gene sets were most abundant. Every node (red) represents a single overexpressed gene set and the size of the node indicates the size of the gene set. Every line (green) represents overlap between gene sets. Node numbers represent the corresponding gene set as listed in Supplementary Dataset 2. (B) Heatmaps of mRNA (left) and protein expression (right) of genes ($\log_2$ values and row-scaled) from the enriched genes from the cell cycle gene sets (signal-to-noise ratio > 0.1). (C) Overlapping networks of 102 protein (pink) and 142 mRNA (blue) expression-enriched cell cycle genes indicate unique and shared (grey) genes. Some genes evaluated by mRNA expression were not included in the proteomics dataset and are indicated without border. Genes within this network can be found in Supplementary Table S3.

(CDC) 25A and polo-like kinases (PLK) 1, 2 and 4.

Next, to examine whether the elevated mRNA expression of these 142 selected cell cycle-related genes was reflected in patient tumours, we exploited expression data from The Cancer Genome Atlas (TCGA). Hierarchical clustering uncovered a specific set of 46 genes that was consistently expressed at higher levels in a subgroup of the breast cancer patients (Figure 5A). This cluster mainly consisted of tumours from basal-like, HER2-enriched and luminal B PAM50 subtypes. Although most of the TNBC tumours had high expression of these genes, also within the TNBC subset, these genes were differentially expressed (Figure 5B). The hierarchical clustering revealed three clusters of TNBC tumours, with either high (42%), intermediate (34%) or low (24%) expression of the genes. The 46 genes selected from these differential cluster in patients still also subdivide TNBC cell lines in a similar manner as the original 142 genes (Supplementary Figure S6).

Elevated cell cycle gene expression network provides novel targets for bypassing Akt-i/MEK-i resistance

Next, we investigated whether the aberrant cell cycle gene expression network found in Akt-i/MEK-i-resistant Group 3 cell lines could be an alternative target for this subgroup. Pathway analysis of the overexpressed cell cycle genes visualised core components, including CDC25A, CDK2 and CDK4 (Figure 6A). Moreover, elevated E2F1 and DP1, together with low expression of RB1, were central in this pathway. Targeting the downstream CDKs affected by these transcription factors and CDC25A may therefore have detrimental direct and indirect effects on TNBC cell proliferation. Indeed, CDK inhibition by flavopiridol or dinaciclib strongly inhibited the growth of the Akt-i/MEK-i-resistant Group 3 cell lines (Figure 6B). Contrastingly, Group 1 cell lines HCC1806 and MDA-MB-435s showed a relatively reduced sensitivity to dinaciclib and flavopiridol, with an average 2-3-fold increase in IC50 for both CDK inhibitors (Figure 6B, Supplementary Table S4).

Moreover, dinaciclib at 10 nM or 31.6 nM completely inhibited phosphorylation of RB1 at Ser780, an event specifically mediated by the CDK4/6-Cyclin D1 complex, in both HCC1806 and SUM159PT cells, indicative of cell cycle arrest (Figure 6C). Importantly, flavopiridol at 100 nM moderately reduced RB1-Ser780 levels in double-resistant Group 3 cell line SUM159PT but not in Akt-i-resistant Group 1 HCC1806 cells. Similarly, CDK9/CDK7-mediated phosphorylation of RNA Polymerase II's C-terminal domain (POLR2A) at Ser2/5 was abolished by dinaciclib in both cell lines whereas flavopiridol exclusively reduced POLR2A phosphorylation in SUM159PT cells. Dinaciclib induced cleavage of PARP1 in both cell lines, whilst flavopiridol-induced PARP1 cleavage was solely visible in SUM159PT cells. Concomitant depletion of BH3-only family member MCL-1 and induction of H2AX phosphorylation at Ser139 in double-resistant SUM159PT cells suggested induction of apoptosis and DNA damage response signalling. These effects were absent in HCC1806 cells after exposure to flavopiridol. Notwithstanding this differential sensitivity, the Group 2 cell lines BT20 and HCC70 were equally as sensitive to the CDK inhibitors as Group 3





Figure 5. Expression of the Akt-i/MEK-i-resistant cell cycle gene network in breast cancer patients. (A) Clustering of all breast cancer patients (n=1093) from the TCGA database by gene expression levels of 134 expressed genes out of the 142 mRNA cell cycle genes found overexpressed in the Akt-i/MEK-i-resistant cell lines. The black box shows a cluster of 46 genes that was consistently expressed at a higher level in one of the two subsets of patients. Genes in bold indicate overexpressed genes that were shared in mRNA and protein expression GSEA of the Akt-i/MEK-i-resistant cell lines. Colour annotations indicate hormone receptor (HR) status and PAM50 subtypes of the patients. (B) Clustering of TNBC patients (n=120) from the TCGA database based on expression of these 46 genes.



cell lines (Figure 6B). These data therefore suggest that CDK inhibitors which target the aberrant cell cycle profile are especially, but not exclusively, effective in Akt-i/MEK-i-resistant Group 3 cell lines.

Discussion

Although various potential targets characterise TNBC tumours, no effective clinical targeted therapy is available for this aggressive disease. Using a kinase inhibitor screen in a broad panel of TNBC cell lines, we mapped the responses to inhibition of various kinase targets and found that MEK and Akt inhibitors differentially affected TNBC cell proliferation. The ERK and Akt signalling programs are critical in various aspects of cancer biology, and MEK and Akt inhibitors have entered the clinic for various types of cancer^{17,18}. Moreover, TNBC is often accompanied by genetic aberrations in upstream modulators of these pathways. As drug resistance to MEK and Akt inhibitors is not fully understood, this study further focussed on exploring the heterogeneity in these responses. We here demonstrate that MEK and Akt double resistance is associated with the elevated expression of a cell cycle gene network, while inhibition thereof effectively reduced cell proliferation in these MEK and Akt inhibitor double-resistant cell lines.

In this research we have focused on studying the differential responses to MEK and Akt inhibitors, as the screening indicated the most clear and consistent differences between responses to these inhibitors among the TNBC cell lines. Although Raf and PI3K inhibitors are also promising candidates under clinical development, we did not find consistent responses upon treatment with these classes of inhibitors. This might be due to off-target effects of such inhibitors or due to different mechanisms of action. Moreover, the initial screening of the kinase inhibitor library was limited to testing the inhibitors at a single concentration of 1 μ M. Therefore, we do not exclude that other classes of inhibitors may also differentially affect TNBC cell proliferation at higher or lower concentrations.

Previous studies have indicated that MEK or Akt inhibitor resistance in cancer can be caused by crosstalk between the PI3K/Akt/mTOR or RAF/MEK/ERK pathways^{7,8,19}. Therefore, these studies suggest that combination therapy with MEK and Akt (or PI3K) inhibitors will reverse this resistance. In this study, we did not observe induction of the parallel pathways after Akt or MEK inhibition, with the exception of SUM159PT cells. Combination therapy also did not sufficiently sensitise the Akt- and MEK inhibitor-resistant cells to either therapy. These results suggest that crosstalk is not an essential mechanism of combined Akt-i and MEK-i resistance in TNBC. Indeed, even though various studies demonstrate synergistic effects of combination therapy, these did not disrupt cell viability completely^{7,8,19}. Importantly, combination therapy with MEK and Akt inhibitors has also not shown promising results in clinical trials, as beneficial effects over single treatment are hardly obtained, instead causing more severe side effects^{13,14,20}. For these reasons we sought to find another strategy to overcome the

Chapter 2

resistance in MEK-i and Akt-i-resistant cells.

Our results demonstrate that Akt inhibitor-resistant cell lines can be distinguished from MEK inhibitor-resistant lines by increased levels of p-MEK and low levels of p-Akt. Additionally, mutations in PTEN, PI3KCA and/or PI3KR1 characterise MEK inhibitor-resistant but not Akt inhibitor-resistant cell lines. Similar observations were made in other cancer types by others⁷⁻⁹. However, these features do not entirely explain the observed resistance phenotypes in our panel of TNBC cell lines. Here, we further explored the underlying mechanisms responsible for double resistance to both Akt and MEK inhibitors. To this end, we took advantage of our unique transcriptome and proteome dataset of the entire TNBC cell line panel. Using large-scale gene set enrichment analysis, we revealed a 142-gene and 102-protein cell cycle-enriched network associated with Akt and MEK inhibitor double resistance. Importantly, 46 of these genes subdivides all breast cancer patients, as well as TNBC patients, into separate groups based on their gene expression. The majority of TNBC patients had high expression of these genes, which is line with that so far, most TNBC patients are not responsive to MEK and Akt inhibitor treatments^{13,14,20-23}. Yet, a minority of the TNBC patients may thus be sensitive to MEK or Akt inhibitors, depending on their p-MEK/p-Akt levels. Thus, stratification of patients in clinical trials of MEK or Akt inhibitors based on the features described in this study may reveal beneficial effects that would otherwise be neglected. However, further studies are needed to translate the associations found here to patient treatment responses. Moreover, also the luminal B and HER2-enriched hormone-positive breast cancers have a higher expression of this gene signature compared to the luminal A subtype, suggesting that for hormone-positive breast cancers the PAM50 subtyping may already be predictive. Nevertheless, as the findings in this study are based on TNBC cell lines, this needs to be explored further.

The overexpression of the cell cycle genes may render signals from Akt and MEK redundant. No studies have previously linked such a profile to Akt and MEK inhibitor resistance in TNBC. However, various studies in other cancer types have recently demonstrated the role of the cell cycle in this resistance by confirming synergy between inhibitors of the PI3K/MAPK pathway and inhibitors of the cell cycle, such as CDK and PLK inhibitors²⁴⁻³⁰. These findings suggest that the enhanced expression and activity of cell cycle machinery components may have an important role in resistance to Akt and MEK inhibitors, not only in TNBC, but also in other cancer types.

Our data demonstrate that inhibition of CDKs that determine cell cycle progression and transcription can effectively kill TNBC cells that are otherwise resistant to Akt and MEK inhibitors. Although our initial screening did not show clear differences in responses to CDK inhibitors at 1 μ M, further evaluation at lower concentrations did reveal differential responses. For example, the pan-CDK inhibitors dinaciclib and flavopiridol inhibited proliferation of SUM159T cells that were resistant to both Akt-i and MEK-i. Interestingly, some, but not all, Akt or MEK inhibitor-sensitive cell lines were more resistant to these compounds compared to MEK-i/Akt-i double-resistant

cell lines. Thus, these compounds are especially, but not exclusively, effective against this group and provide possible alternative treatments for overcoming Akt and MEK inhibitor double resistance. Notably, both lethal and sub-lethal concentrations of dinaciclib inhibited RB1 and POLR2A phosphorylation in HCC1806 cells, confirming that its relative insensitivity to this agent is not related to inefficient target inhibition, unlike flavopiridol. The superior activity of dinaciclib compared to flavopiridol was also evidenced by the complete abrogation of RB1 and POLR2A phosphorylation at concentrations ten times lower than those required for flavopiridol to elicit a moderately comparable effect, which was only visible in MEK-i/Akt-i double-resistant SUM159PT cells. As dinaciclib and flavopiridol are more effective in the MEK-i/Akt-i resistant cell lines this may suggest that also for MEK-i/Akt-i resistant TNBC patients these treatments could be alternative options. This strategy could potentially be improved by more selective CDK inhibitors that are currently being developed. Nevertheless, the increased sensitivity could expand the therapeutic window to circumvent the side effects that are associated with flavopiridol and dinaciclib.

To conclude, this study describes the molecular features that can discriminate between Akt-i and MEK-i single agent-sensitive subsets of TNBC cells as well as double agent-resistant TNBC cells. For double-resistant cells we uncovered a high expression of a cell cycle gene network. Accordingly, these double-resistant cells are relatively sensitive to inhibitors of CDKs. Moreover, a number of these genes are also differentially expressed in TNBC patients. Since our study describes clinically relevant features that can subdivide TNBC cells into their Akt and MEK inhibitor response profile, these features may also facilitate the prediction of response in patients. Future mechanistic studies may reveal the origin of the aberrant cell cycle network, which could supplement this study by providing additional alternative targets and simplified biomarkers for clinical assessment. Altogether, this and future studies could therefore lead to a biomarker-based therapeutic strategy for treating TNBC patients with Akt, MEK and/or CDK inhibitors.

Acknowledgements

This work was supported by the ERC Advanced grant Triple-BC (grant number 322737) and the Dutch Cancer Society project (grant number 2011-5124).

Competing interests

The authors declare no competing interest.

Data availability

The cell line transcriptomics and TNBC patient gene expression datasets analysed in this study were available from the GEO data repository (GEO: GSE41313) and

TCGA-BRCA database respectively. The proteomics dataset analysed in the current study is available upon reasonable request.


References

1. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer* **109**, 1721-1728 (2007).
2. Cortazar, P. *et al.* Pathological complete response and long-term clinical benefit in breast cancer: the CT-NeoBC pooled analysis. *The Lancet* **384**, 164-172 (2014).
3. Dent, R. *et al.* Triple-negative breast cancer: clinical features and patterns of recurrence. *Clinical cancer research* **13**, 4429-4434 (2007).
4. Network, C. G. A. Comprehensive molecular portraits of human breast tumors. *Nature* **490**, 61 (2012).
5. Craig, D. W. *et al.* Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities. *Molecular Cancer Therapeutics* **12**, 104 (2013).
6. Saini, K. S. *et al.* Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. *Cancer treatment reviews* **39**, 935-946 (2013).
7. Hoefflich, K. P. *et al.* In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. *Clinical Cancer Research* **15**, 4649-4664 (2009).
8. Mirzoeva, O. K. *et al.* Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. *Cancer research* **69**, 565-572 (2009).
9. Sangai, T. *et al.* Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. *Clinical Cancer Research* **18**, 5816-5828 (2012).
10. Hirai, H. *et al.* MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. *Molecular cancer therapeutics* **9**, 1956-1967 (2010).
11. Duncan, J. S. *et al.* Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. *Cell* **149**, 307-321 (2012).
12. Maiello, M. R. *et al.* EGFR and MEK blockade in triple negative breast cancer cells. *Journal of cellular biochemistry* **116**, 2778-2785 (2015).
13. Shimizu, T. *et al.* The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. *Clinical Cancer Research* **18**, 2316-2325 (2012).
14. Genentech. NCT01562275: A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors. <http://clinicaltrials.gov/show/NCT01562275> (2000-2016).
15. Lehmann, B. D. *et al.* Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *The Journal of clinical investigation* **121**, 2750-2767 (2011).
16. Lin, J. *et al.* Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. *Clinical Cancer Research* **19**, 1760-1772 (2013).
17. LoRusso, P. M. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. *Journal of Clinical Oncology* **34**, 3803-3815 (2016).
18. Zhao, Y. & Adjei, A. A. The clinical development of MEK inhibitors. *Nature reviews Clinical oncology* **11**, 385-400 (2014).
19. Lee, J. *et al.* Comprehensive Two-and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. *Journal of Cancer* **6**, 1306-1319 (2015).
20. National Cancer Institute. NCT01658943: Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy. <http://clinicaltrials.gov/show/NCT01658943> (2000-2016).
21. Rinehart, J. *et al.* Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. *Journal of clinical oncology* **22**, 4456-4462 (2004).
22. Kim, S.-B. *et al.* Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet Oncology* **18**, 1360-1372 (2017).
23. Infante, J. R. *et al.* A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. *European journal of cancer* **49**, 2077-

- 2085 (2013).
24. Morgan-Lappe, S. *et al.* RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. *Oncogene* **25**, 1340-1348 (2006).
25. Vora, S. R. *et al.* CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. *Cancer cell* **26**, 136-149 (2014).
26. Lee, M. S. *et al.* Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. *Oncotarget* **7**, 39595-39608 (2016).
27. Eliades, P. *et al.* A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. *Cancer biology & therapy* **17**, 778-784 (2016).
28. Posch, C. *et al.* Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma. *Journal of Investigative Dermatology* **135**, 2475-2483 (2015).
29. Beale, G. *et al.* Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. *British Journal of Cancer* **115**, 682-690 (2016).
30. Hu, C. *et al.* Combined inhibition of cyclin-dependent kinases (dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models. *Molecular cancer therapeutics* **14**, 1532-1539 (2015).
31. Zhang, Y. *et al.* Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. *Breast cancer research* **13**, R52 (2011).
32. Qin, Y. *et al.* cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac. *British journal of pharmacology* **165**, 1137-1150 (2012).
33. Forbes, S. A. *et al.* COSMIC: somatic cancer genetics at high-resolution. *Nucleic acids research* **45**, D777-D783 (2016).
34. Riaz, M. *et al.* miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. *Breast cancer research* **15**, R33 (2013).
35. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences* **102**, 15545-15550 (2005).
36. Mootha, V. K. *et al.* PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. *Nature genetics* **34**, 267-273 (2003).
37. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. *PloS one* **5**, e13984 (2010).
38. Colaprico, A. *et al.* TCGAAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic acids research*, gkv1507 (2015).
39. Kolde, R. Pheatmap: Pretty Heatmaps. R package version 1.0. 2 (2015).


Supplementary Data

For Supplementary Dataset 1 and 2 and enlarged figures, please find the online version of this article (<https://www.nature.com/articles/s41598-019-49809-3>).




Supplementary Figure S1. Clustered kinase inhibitors differentially affecting TNBC cell proliferation. Enlarged and annotation version of the clustered branch of differentially effective kinase inhibitors from Figure 1A. The black box highlights mainly MEK and Akt inhibitors. Low Z-scores (red) indicate reduced cell proliferation, whereas high Z-scores indicate resistance (blue) upon treatment with the kinase inhibitors (1 μ M).



MEK and Akt inhibitor resistance in TNBC




Supplementary Figure S2. Proliferative responses to MEK, Akt, Raf and PI3K inhibitors (1 μ M) among TNBC cell lines. Low Z-scores (red) indicate reduced cell proliferation, whereas high Z-scores indicate resistance (blue) upon treatment with the kinase inhibitors.



Supplementary Figure S3. Sensitivity profiling in TNBC cell lines. Validation of Akt-i/MEK-i sensitivity classifications from primary screening (Figure 1B). Proliferative responses of cell lines to increasing concentrations (0.001-10 μ M) of selumetinib (MEK-i) and ipatasertib (Akt-i) are shown.





Supplementary Figure S6. Expression of the 142 cell cycle genes and the selected 46 clinically differentially expressed genes in TNBC cell lines. The mRNA expression of the 142 cell cycle genes, as given in Figure 4B, and of the later selected 46 clinically differentially expressed genes, as shown in Figure 5, in the TNBC cell lines is shown.

Supplementary Table S1. IC50's for Akt and MEK inhibitors. To validate the resistance to Akt and/or MEK inhibitors, cells were treated with a dose range (0.01 – 3.16 μ M) of inhibitors in three technical replicates in two independent experiments. Proliferation was evaluated using an SRB assay and IC50's were calculated using GraphPad Prism. If 50% of proliferation was not reached, IC50's are noted as >3.16. For the case of more than 50% reduction of growth at the lowest concentration, IC50's were noted as <0.01.

	IC50 (μ M)	Akt-i resistant			MEK-i resistant			Akt-i & MEK-i double resistant		
		MDA-MB-231	MDA-MB-435s	HCC1806	MDA-MB-468	BT20	HCC70	SKBR7	SUM159PT	MDA-MB-436
Akt-i	MK-2206	>3.16	>3.16	>3.16	0.30	>3.16	0.26	>3.16	1.35	>3.16
	GDC-0068	>3.16	>3.16	>3.16	0.16	0.38	0.21	>3.16	>3.16	>3.16
	AZD5363	>3.16	>3.16	>3.16	0.15	0.34	0.17	>3.16	~3.16	>3.16
	GSK690693	>3.16	>3.16	>3.16	>3.16	0.15	1.31	>3.16	>3.16	>3.16
MEK-i	Selumetinib	0.05	0.03	>3.16	>3.16	>3.16	>3.16	>3.16	2.74	>3.16
	MEK-i162	<0.01	<0.01	7.617	>3.16	>3.16	>3.16	>3.16	~3.16	>3.16
	Trametinib	<0.01	<0.01	<0.01	0.03	>3.16	>3.16	>3.16	NA	NA
	PD318088	0.15	<0.01	<0.01	0.32	>3.16	>3.16	>3.16	>3.16	>3.16
	PD184352	0.79	0.12	<0.01	>3.16	>3.16	>3.16	>3.16	>3.16	>3.16
	PD032590	<0.01	<0.01	0.48	0.53	>3.16	>3.16	>3.16	>3.16	>3.16
	Pimasertib	<0.01	<0.01	2.27	2.39	>3.16	>3.16	>3.16	>3.16	>3.16
	Refametinib	<0.01	<0.01	<0.01	>3.16	>3.16	>3.16	>3.16	~3.16	>3.16
	TAK-733	<0.01	<0.01	<0.01	0.27	>3.16	>3.16	>3.16	~3.16	>3.16
	AZD8330	<0.01	<0.01	<0.01	>3.16	>3.16	>3.16	>3.16	>3.16	>3.16

MEK and Akt inhibitor resistance in TNBC

Supplementary Table S2. Common mutations in cell lines in components of the PI3K, MAPK, cell cycle and DNA damage repair pathways. Mutations in Cancer Gene Census genes were deduced from the COSMIC database (<http://cancer.sanger.ac.uk/cosmic>).

	PI3K	MAPK	PI3K/ MAPK	Cell cycle	DNA damage repair
1) Akt-i resistant	HCC1143		FGFR2	TP53	
	MDA-MB-435s	BRAF		TP53, CDKN2A, EP300	
	MDA-MB-231	BRAF,NF1	PDGFRA, KRAS	TP53, CDKN2A	
	HCC1806	NFATC2, ROS1	PDGFRB	TP53, CDKN2A	
	SUM229PE		KRAS	CDKN2A	
	SUM52PE			TP53, CDKN2A	
	SUM149PT			TP53, CDKN2A, EP300	BRCA1
2) MEK-i resistant	HCC70	PTEN		TP53, RB1	
	MDA-MB-453	PIK3CA, PTEN	ROS1	CREBBP, ATM, STAG2	CREBBP, ATM
	SUM185PE	PIK3CA		TP53	
	BT20	PIK3CA		ATM, CDKN2C, CDKN2A, RB1, TP53	MLH1
	Hs578T	PIK3R1	NF1	TP53, CDKN2A, POLE	POLE
	MDA-MB-468	PTEN	CACNA1D, MAP3K13	TP53, CDKN2A, RB1	
3) Akt/MEK-i resistant	BT549	PTEN	FGFR1	TP53, RB1, BUB1B, (DCTN1), PCM1	MUTYH
	SKBR7		KRAS, NRAS	CDKN2A	
	HCC1937	PTEN	MAPK13	TP53, RB1	BRCA1
	MDA-MB-436	PIK3R1		TP53, RB1	BRCA1, POLE
	HCC38		IKBKB	TP53, CDKN2A	PMS2, BRCA1*
	SUM159PT	PIK3CA	HRAS	TP53	
	SUM1315MO2	PIK3CA		TP53	BRCA1

* Methylation

Chapter 2

Supplementary Table S3. Enriched cell cycle genes in Akt-i/MEK-i resistant group 3 cell lines.
From the significantly enriched, cell cycle associated, gene sets, enriched genes or proteins (signal-to-noise < 0.1) were used for further analysis.

mRNA expression		Protein expression		Shared	
PROBE	Signal-to-noise	PROBE	Signal-to-noise	PROBE	Signal-to-noise (mRNA)
SNAP25	0.710	SEC13	0.797	PSMD11	0.447
STX11	0.640	RUVBL1	0.765	PSMC2	0.379
KAT2B	0.530	PSMC4	0.737	SEC13	0.124
PPP2R3B	0.528	PSMD3	0.737	PSMD3	0.107
SGOL1	0.499	PSMA3	0.693	PSMD1	0.106
PTRF	0.489	PSMD1	0.678	PCM1	0.409
TUBB4A	0.448	PSMA4	0.670	PSMD12	0.103
PSMD11	0.447	CKAP5	0.666	PSMA7	0.139
CDC25A	0.425	YWHAG	0.647	PSMB7	0.117
STX2	0.423	PSMC2	0.632	ORC5	0.240
PCM1	0.409	PSMD11	0.631	RPS27	0.108
CENPI	0.393	PSMD12	0.611	PSMD9	0.375
PSMC2	0.379	RUVBL2	0.604	CCNB1	0.170
PSMD9	0.375	PSMD4	0.589	CDC23	0.267
NINL	0.360	PSMA7	0.574	GIN54	0.143
POLR3D	0.332	PSMB7	0.571	ACTR1A	0.150
RFC3	0.316	PSMA1	0.569	CUL1	0.164
HIST1H2A	0.308	SKP1	0.557	ANAPC7	0.141
CENPO	0.298	RPS27	0.545	NDC80	0.104
PPP2R1B	0.293	CDK4	0.533	CDK2	0.138
RPA4	0.289	PSME2	0.526	CDK5RA	0.180
GTF3C3	0.284	PSMC5	0.514	TYMS	0.228
GTF2H2	0.283	PSMD8	0.504	SPC25	0.209
SNAPC1	0.277	RBX1	0.498	PPP2CB	0.107
TUBA1A	0.274	NUDC	0.487	ZWILCH	0.154
POLR1A	0.274	PSMC1	0.478	ERCC6L	0.175
CDK6	0.269	PSME1	0.478	KIF2A	0.117
CDC23	0.267	PSMB4	0.472	GIN51	0.115
LIN54	0.250	PSMD13	0.466	SYNE1	0.112
STX4	0.245	DCTN2	0.445	MAX	0.116
CEP250	0.244	RPS27A	0.443		
ORC5	0.240	CLASP1	0.442		
CDC6	0.235	UBE2E1	0.440		
TFDP1	0.232	MAGED1	0.438		
MCM6	0.232	DCTN3	0.435		
ATRIP	0.229	ORC5	0.424		
TYMS	0.228	UBE2I	0.423		
WRAP53	0.223	CUL5	0.422		
NUP43	0.222	CCNB1	0.415		
BUB1	0.220	GIN54	0.414		
BRCA1	0.218	PSMD7	0.382		
VAMP1	0.218	ACTR1A	0.375		
E2F1	0.211	PAFAH1	0.365		
STX1B	0.210	PSMB1	0.364		
SPC25	0.209	PSMC3	0.361		
TUBG1	0.205	NDC80	0.360		
ERCC6	0.205	PSMD6	0.355		
SKA1	0.201	CLIP1	0.352		
CCNE1	0.199	XPO1	0.347		
ORC1	0.199	ANAPC2	0.338		
TAOK1	0.192	CUL1	0.338		
CCNE2	0.190	PCM1	0.336		
HIST1H4J	0.187	ANAPC7	0.333		
GTF2H2B	0.187	LMNA	0.331		
CCNA2	0.184	KIF2C	0.328		
CDKN2C	0.181	CDK2	0.316		
CDK5RAP	0.180	TUBGCP	0.314		
TUBGCP5	0.179	TCEB2	0.309		
BTRC	0.178	CDC23	0.308		
PSMB2	0.177	PSMB5	0.288		
ERCC6L	0.175	DYNLL1	0.279		
CENPK	0.172	PSMB8	0.277		
CCNB1	0.170	CDK5RA	0.255		
POLE2	0.169	PSMD2	0.251		
CEP135	0.167	NUF2	0.248		
CUL1	0.164	PSMD9	0.239		
RBBP4	0.163	CETN2	0.233		
DNA2	0.161	PSMC6	0.232		
DIDO1	0.160	DYNC112	0.232		
PPP2R2A	0.156	KIF20A	0.226		

(Table continued on next page ►)

MEK and Akt inhibitor resistance in TNBC

CEP72	0.156	RPA1	0.226
ZWILCH	0.154	PPP2CB	0.223
HAUS2	0.152	HSPA2	0.222
CENPH	0.151	PSMD10	0.217
CDC25C	0.150	PPP2R1	0.206
ACTR1A	0.150	FEN1	0.200
TAF1B	0.147	TYMS	0.198
MCM10	0.147	MNAT1	0.178
UBTF	0.145	PPP2R5	0.177
MCM4	0.144	ZWILCH	0.176
CDC27	0.144	ANAPC5	0.176
ANAPC10	0.143	PRKACA	0.166
LIN52	0.143	ORC2	0.166
GIN54	0.143	SEH1L	0.155
SNAPC3	0.142	YWHAE	0.153
SNAPC4	0.142	DCTN1	0.150
SGOL2	0.142	PSMA2	0.150
PLK4	0.141	HSP90A	0.149
ANAPC7	0.141	NUP37	0.148
MIS18A	0.139	SPC25	0.147
PSMA7	0.139	KIF2A	0.143
CDK2	0.138	TERF2	0.141
ZW10	0.138	GIN51	0.141
KIF18A	0.138	PAK2	0.132
CDCA8	0.136	ERCC6L	0.127
CCDC99	0.135	SYNE1	0.120
PRIM2	0.134	MAX	0.116
CEP41	0.134	PSMD5	0.112
TFAM	0.134	CDC16	0.106
CDC20	0.132	PSMA5	0.104
POLR3H	0.129	DYNC1H	0.103
CEP76	0.126	MAPRE1	0.101
POLA1	0.126		
AURKA	0.125		
BIRC5	0.124		
SEC13	0.124		
CEP63	0.123		
SMC1A	0.123		
POLR1D	0.122		
BRF2	0.119		
KIF2A	0.117		
PSMB7	0.117		
B9D2	0.117		
SPC24	0.117		
MAX	0.116		
STX1A	0.116		
CEP164	0.115		
SMARCA5	0.115		
CDKN2A	0.115		
PLK1	0.115		
ORC3	0.115		
GIN51	0.115		
CDC26	0.113		
SYNE1	0.112		
RAD17	0.112		
DSN1	0.111		
HIST1H2A	0.110		
POLR3GL	0.110		
CDK7	0.109		
RPS27	0.108		
PSMD3	0.107		
PPP2CB	0.107		
CASC5	0.107		
PSMD1	0.106		
MYBL2	0.106		
ORC6	0.105		
NDC80	0.104		
SSNA1	0.104		
PSMD12	0.103		
SSB	0.101		
MCM2	0.100		
MCM8	0.100		

Chapter 2

Supplementary Table S4. Differential sensitivity of group 3 cell lines to CDK inhibitors dinaciclib and flavopiridol. IC50 values for selected cell lines from Group 1 (Akt-i-resistant), Group 2 (MEK-i-resistant) and Group 3 (Akt-i/MEK-i double-resistant) for pan-CDK inhibitors dinaciclib and flavopiridol. IC50 values were calculated using non-linear regression fitting in GraphPad Prism.

	Group 1 (Akt-i-resistant)		Group 2 (MEK-i-resistant)		Group 3 (Akt-i/MEK-i-resistant)		
IC50 (μM)	HCC1806	MDA-MB-435s	BT20	HCC70	SKBR7	MDA-MB-436	SUM159PT
Dinaciclib	0.297	0.3121	0.207	0.137	0.147	0.110	0.154
Flavopiridol	0.489	0.2758	0.150	0.125	0.0952	0.178	0.177